US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion
Executive Summary
CDER Director Cavazzoni also wants to loosen conflict of interest rules and improve technology for remote meetings. Given FDA’s approval of Aduhelm, her comments, made in a prerecorded interview for the BIO Digital annual meeting, may raise some eyebrows. Industry is also working on recommendations for the agency on the topic.
You may also be interested in...
Expect More Temporary Members Voting In US FDA Advisory Committees
Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.
Ahead Of Sarepta Advisory Committee, FDA Feels Congressional Pressure About Public Participation
Senators write US FDA commissioner seeking ‘fulsome public input’ at panel review of DMD gene therapy. The open public hearing is scheduled to run an average amount for a neurodegenerative advisory committee – but less than half the time of the OPH at the last Sarepta meeting.
Sarepta’s DMD Gene Therapy, Like Exondys 51, Is Foundational, Advocates Argue
The Duchenne muscular dystrophy candidate should be approved because it will help grow development in the space, patient groups argue, not just because of the value the gene therapy could provide to those receiving the treatment itself.